Engineered immune cells take on deadly childhood brain cancer
NCT ID NCT07513194
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment for children with a rare, aggressive brain tumor called ATRT that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and attack the tumor, plus added signals to help them survive longer. The main goals are to find a safe dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI reads MRI scans to reveal hidden brain tumor types in children before surgery
- Spinal tap could replace brain surgery for young tumor patients
- Promising drug targets rare childhood tumors in new trial
- Experimental drug DFMO offered to kids with rare cancers
- Killer virus turned against childhood brain cancer
- Immune cells engineered to fight brain cancer in kids